AMY YAGER: Open Payments
NPI 1396996948 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,754 in 65 payments from 11 companies in 2025. Trend: 2023 $5,016 · 2024 $3,471 · 2025 $1,754
Food & beverage: $1,754
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $456 |
| Alkermes, Inc. | 11 | $447 |
| ABBVIE INC. | 6 | $183 |
| Axsome Therapeutics, Inc. | 3 | $154 |
| Otsuka America Pharmaceutical, Inc. | 2 | $143 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, Auvelity, VIVITROL, ABILIFY MAINTENA, LYBALVI, HETLIOZ.
Industry payments across NE — which companies pay providers there.
